Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7448230 | 0.87 | MME (0.55) | MMEMAPK8MAPK10MEN1RAB9A | |
| SCHEMBL6938890 | 0.76 | MME (0.61) | MMEMAPK8MAPK10WNT3A | |
| SCHEMBL7448229 | 0.75 | MME (0.54) | MMEMAPK8MAPK10WNT3ARIOK2 | |
| SCHEMBL6938887 | 0.71 | MME (0.51) | MMEMAPK8MAPK10WNT3ARIOK2 | |
| SCHEMBL7448233 | 0.71 | MME (0.59) | MMEWNT3ARIOK2 | |
| SCHEMBL7445870 | 0.64 | MME (0.55) | MMEMEN1RAB9AKMT2A | |
| SCHEMBL1553496 | 0.62 | CNR1 (0.60) | WNT3AEGFRBUB1CNR1 | |
| SCHEMBL17872892 | 0.62 | EGFR (0.69) | MAPK8MAPK10WNT3AEGFRMEN1 | |
| SCHEMBL28655226 | 0.61 | NPC1 (0.65) | MAPK8MAPK10EGFRMEN1RAB9A | |
| SCHEMBL5251219 | 0.61 | EGFR (0.57) | MAPK8MAPK10WNT3ARIOK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885MAPK8 4325/4885MAPK10 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.